Emerald Health Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was CAD 2.11 million compared to CAD 3.37 million a year ago. Net loss was CAD 9.14 million compared to CAD 11.49 million a year ago. Basic loss per share from continuing operations was CAD 0.043 compared to CAD 0.057 a year ago. For the nine months, revenue was CAD 7.4 million compared to CAD 8.74 million a year ago. Net loss was CAD 26 million compared to CAD 35.09 million a year ago. Basic loss per share from continuing operations was CAD 0.12 compared to CAD 0.19 a year ago.